{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:05:10Z","timestamp":1779966310606,"version":"3.53.1"},"reference-count":25,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Palmoplantar psoriasis (PP) is a challenging variant of psoriasis that affects high-impact areas such as palms and soles and significantly impairs quality of life despite often limited body surface involvement. Conventional topical and systemic therapies may be insufficient, and evidence on biologic treatments for this specific phenotype remains limited. Bimekizumab (BKZ), a monoclonal antibody targeting IL-17A and IL-17F, has shown high efficacy in plaque psoriasis. This study aimed to evaluate the real-world effectiveness and rapidity of action of BKZ in patients with palmoplantar psoriasis compared with patients with psoriasis vulgaris (PV). Methods: We conducted a multicenter retrospective cohort study using data from 22 Italian dermatological units within the IL-PSO (Italian Landscape-Psoriasis) database. Adult patients treated with BKZ between November 2022 and October 2024 were included and categorized into three groups: isolated PP, PP associated with PV (PP + PV), and PV without palmoplantar involvement. Clinical outcomes included the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and pruritus Visual Analogue Scale (VAS). Outcomes were assessed at baseline, week 4, and week 16. Results: A total of 47 patients were included. The baseline PASI was lower in the PP group compared with the PP + PV and PV groups, whereas the DLQI was highest in patients with isolated PP. Rapid clinical improvement was observed in all groups. The mean % PASI reduction at week 4 was 60.5%, 65.1%, and 77.0% in the PP, PP + PV, and PV groups, respectively, increasing to 94.8%, 90.4%, and 91.8% at week 16. The proportion of patients achieving complete clearance (PASI = 0) at week 16 was 73.3% (11\/15), 68.2% (15\/22), and 70.0% (7\/10), respectively. Significant improvements were also observed in DLQI and pruritus scores over time. No significant safety concerns emerged. Conclusions: In this real-world multicenter cohort, bimekizumab demonstrated rapid and high efficacy in patients with palmoplantar psoriasis, both isolated and associated with psoriasis vulgaris. These findings support the use of BKZ as an effective therapeutic option for psoriasis involving high-impact areas, as the palmoplantar, although larger studies are needed to confirm these results.<\/jats:p>","DOI":"10.3390\/jcm15114168","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:57:43Z","timestamp":1779962263000},"page":"4168","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study\u2014IL PSO (Italian Landscape PSOriasis)"],"prefix":"10.3390","volume":"15","author":[{"given":"Martina","family":"Burlando","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, 16132 Genova, Italy"},{"name":"Section of Dermatology, IRCCS Azienda Ospedaliera Metropolitana, Ospedale San Martino, 16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-4523","authenticated-orcid":false,"given":"Lidia","family":"Sacchelli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola Malpighi, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Bettacchi","sequence":"additional","affiliation":[{"name":"UOC of Dermatology, Hospital of Macerata, ASUR Marche AV3, 62100 Macerata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Alexandra","family":"Brunasso Vernetti","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Galliera Hospital, 16128 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7433-9283","authenticated-orcid":false,"given":"Stefano","family":"Caccavale","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Nuovo Policlinico, Luigi Vanvitelli University of Campania, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Nuovo Policlinico, Luigi Vanvitelli University of Campania, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Elisabetta","family":"Cagni","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Dipartimentale di Dermatologia e Venereologia, IRCCS San Gerardo, 20900 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Chersi","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Hospital Clinics Giuliano Isontino (ASUGI), University of Trieste, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4848-3817","authenticated-orcid":false,"given":"Andrea","family":"Conti","sequence":"additional","affiliation":[{"name":"Dermatologic Unit, Department of Surgery, Ospedale Infermi, AUSL Romagna, Viale Settembrini 2, 47923 Rimini, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Biomedical Sciences, Humanitas University, 20089 Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-8524","authenticated-orcid":false,"given":"Domenico","family":"D\u2019amico","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Hospital Facility \u201cA. Pugliese\u201d, UOC \u201cR.Dulbecco\u201d, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and Surgery, IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-7108","authenticated-orcid":false,"given":"Vito","family":"Di Lernia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-6993","authenticated-orcid":false,"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Giofre\u2019","sequence":"additional","affiliation":[{"name":"U.O.C.di Dermatologia, Dermatology Unit, Azienda Ospedaliera Papardo, 98158 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medicine, University of Verona, 37124 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Graziola","sequence":"additional","affiliation":[{"name":"SCDU Dermatologia, AOU Maggiore Della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Lembo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Licciardello","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Koelliker Hospital, 10134 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Policlinico Consorziale, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-6922","authenticated-orcid":false,"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[{"name":"Psocare Unit, IRCCS Policlinico San Donato, 20097 San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Satolli","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8568-3428","authenticated-orcid":false,"given":"Maria Elena","family":"Susi","sequence":"additional","affiliation":[{"name":"Department of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Manzoni Hospital, ASST-Lecco, 23900 Lecco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele Claudio","family":"Cozzani","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, 16132 Genova, Italy"},{"name":"Section of Dermatology, IRCCS Azienda Ospedaliera Metropolitana, Ospedale San Martino, 16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40257-024-00849-0","article-title":"Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis","volume":"25","author":"Huang","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5114\/ada.2019.89508","article-title":"How frequently does palmoplantar psoriasis affect the palms and\/or soles? A systematic review and meta-analysis","volume":"36","author":"Jankovic","year":"2019","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-3083.2009.03197.x","article-title":"A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients","volume":"23","author":"Tekin","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13555-025-01339-9","article-title":"Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study","volume":"15","author":"Diotallevi","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2024191","DOI":"10.5826\/dpc.1403a191","article-title":"Palmoplantar Psoriasis: Epidemiological and Clinical Features and Impact on Quality of Life","volume":"14","author":"Elinkichari","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2023.04.043","article-title":"Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials","volume":"89","author":"Spencer","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/ITT.S240891","article-title":"The Role of IL-17 Cytokines in Psoriasis","volume":"10","author":"Mosca","year":"2021","journal-title":"Immunotargets Ther."},{"key":"ref_8","first-page":"1133","article-title":"Psoriasis Targeted Therapy: Characterization of Interleukin 17A Expression in Subtypes of Psoriasis","volume":"14","author":"Lee","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jdv.12272","article-title":"Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial","volume":"28","author":"Bissonnette","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","first-page":"1","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Butacu, A.I., Toma, C., Negulet, I.E., Manole, I., Banica, A.N., Plesea, A., Badircea, I.A., Iancu, I., and Tiplica, G.S. (2024). Updates on Psoriasis in Special Areas. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247549"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2024.07.1521","article-title":"A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement","volume":"91","author":"Lebwohl","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"111716","DOI":"10.1016\/j.intimp.2024.111716","article-title":"Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis","volume":"130","author":"Xia","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s13555-024-01295-w","article-title":"Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3\/3b Randomized Controlled Trials","volume":"14","author":"Merola","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bianco, M., D\u2019Oria, F., Ghezzi, G., Ibba, L., Di Giulio, S., Valenti, M., Costanzo, A., Narcisi, A., and Gargiulo, L. (2025). Real-Life Effectiveness and Safety of Bimekizumab in Plaque Psoriasis Involving Difficult-to-Treat Areas: A 52-Week, Retrospective Real-World, Single-Center Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14207412"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"157147","DOI":"10.1016\/j.cyto.2026.157147","article-title":"IL-17F mirrors IL-17A in dermal fibroblasts and synergizes with TNF to drive inflammation in Th17 inflammatory skin diseases","volume":"202","author":"Svraka","year":"2026","journal-title":"Cytokine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"BSR20193266","DOI":"10.1042\/BSR20193266","article-title":"Koebner phenomenon leading to the formation of new psoriatic lesions: Evidences and mechanisms","volume":"39","author":"Ji","year":"2019","journal-title":"Biosci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sacchelli, L., Filippi, F., Loi, C., Clarizio, G., Brunetti, T., La Placa, M., and Bardazzi, F. (2025). Cutaneous Psoriasis and Symptoms (Itch, Pain, and Burning Sensation): A Monocentric Retrospective Study on 299 Patients in Italy. J. Clin. Med., 14.","DOI":"10.20944\/preprints202504.1609.v1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40261-025-01440-z","article-title":"Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis)","volume":"45","author":"Esposito","year":"2025","journal-title":"Clin. Drug Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/PTT.S514249","article-title":"Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events","volume":"15","author":"Fratton","year":"2025","journal-title":"Psoriasis"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Campione, E., Artosi, F., Shumak, R.G., Giunta, A., Argenziano, G., Assorgi, C., Balato, A., Bernardini, N., Brunasso, A.M.G., and Burlando, M. (2024). Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study. Pharmaceuticals, 17.","DOI":"10.3390\/ph17101378"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2024052","DOI":"10.5826\/dpc.1402a52","article-title":"Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience\u2014IL PSO (Italian Landscape Psoriasis)","volume":"14","author":"Orsini","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2563657","DOI":"10.1080\/09546634.2025.2563657","article-title":"Predictive factors for early super response to bimekizumab in 341 patients with psoriasis-a 24-week short-term multicenter real-life experience","volume":"36","author":"Mergen","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_24","first-page":"2672","article-title":"Secukinumab for the treatment of palmoplantar psoriasis: A 2-year, multicenter, real-life observational study","volume":"33","author":"Galluzzo","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2024244","DOI":"10.5826\/dpc.1404a244","article-title":"Palmoplantar Psoriasis Resistant to Adalimumab Successfully Treated with Bimekizumab","volume":"14","author":"Trovato","year":"2024","journal-title":"Dermatol. Pract. Concept."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4168\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:23:00Z","timestamp":1779963780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114168"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114168","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}